Clinical Trial Update: A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ocrelizumab for nephritis due to systemic lupus erythematosus was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Lupus Nephritis, Systemic Lupus Erythematosus | Phase 3 | Status: TERMINATED | Results posted: 2020-12-22